Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome

American Journal of Hematology

Volumn 82, Issue 9, 2007, Pages 849-851

  Navarro, José Tomás ^a   Feliu, Evarist ^a   Grau, Javier ^a   Espinet, Blanca ^b   Colomer, Dolors ^c   Ribera, Josep Maria ^a   Oriol, Albert ^a   Granada, Isabel ^a   Juncà, Jordi ^a   Millá, Fuensanta ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; FLUDARABINE; IMATINIB; TOPOTECAN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG RESPONSE; DRUG WITHDRAWAL; FATALITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MALE; MONOSOMY 7; MYELODYSPLASIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT OUTCOME; CHROMOSOME 7; DISEASE COURSE; GENETICS; IMMUNOLOGY; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 7; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; MONOSOMY; MYELODYSPLASTIC SYNDROMES; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 35748951338     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20859     Document Type: Article

References (17)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of ABL and BCR genes in chronic myelogenous leukemia. Nature 1985;315:550-554.
3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
5. Kantarjian H, Sawyers C, Hochlaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
6. - cells in some CML patients in cytogenetic remision to imatinib but restoration of polyclonal hemtopoiesis in the majority. Blood 2003;101:1941-1949.
7. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794-3800.
8. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-1911.
9. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17:481-487.
10. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2003;17:634-635.
11. Feldman E, Najfeld V, Schuster M, Roboz G, Chadburn A, Silver RT. The emergence of Ph-, trisomy-8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702-707.
12. Terre C, Eclache V, Rousselor P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004;18: 1340-1346.
13. Chee YL, Vickers MA, Stevenson D, Holyoke TL, Culligan DJ. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003;17:634-635.
14. Patchenko P, Klepfish A, Traktenbrot L, Rothman R, Rachmilewitz EA. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML). Am J Hematol 2004;77:420.
15. Zarco MA, Feliu E, Rozman C, et al. Ultrastructural study of erythrocytes containing Pappenheimer bodies in a case of congenital sideroblastic anaemia (CSA). Br J Haematol 1991;78:577-578.
16. Socie G, Deeg JC. Malignancies after hematopoietic stem cell transplantation. Many questions, some answers. Blood 1998;91:1833-1844.
17. Tanaka H, Tanaka K, Oguma N, et al. Effect of interferon-α on chromosome abnormalities in treated chronic myelogenous leukemia patients. Cancer Genet Cytogenet 2004;153:133-143.